Szostak B, Kułaga M, Kasprzak A, Grzybek M, Mazur-Lesińska D, Wielgosz-Biała S, et al. Overview of available treatment and new drug action points in obesity pharmacology. Will GIP, glucagon, amylin replace GLP-1?. Prosp. Pharm. Sc. [Internet]. 2025 May 6 [cited 2025 May 9];23(2):42-9. Available from: https://prospects.wum.edu.pl/index.php/pps/article/view/361